尿畅舒胶囊对去势雌鼠膀胱及血清内皮型一氧化氮合酶、水通道蛋白1的影响

Effect of Niaochangshu Capsule on eNOS, AQP1 in Bladder and Serum of Ovariectomized Female Rats

目的观察尿畅舒胶囊对去势雌鼠膀胱质量、内皮型一氧化氮合酶(eNOS)及水通道蛋白1(AQP1)含量的影响,探讨其治疗绝经后膀胱过度活动症的机理。方法 SD雌性大鼠随机分为空白组、模型组、尼尔雌醇组及尿畅舒组。摘除卵巢建立大鼠雌激素缺乏模型,各给药组给予相应药物灌胃,空白组及模型组灌胃等量生理盐水。给药4周后,测定膀胱质量、膀胱壁厚度;采用ELISA测定血清及膀胱组织中eNOS、AQP1的含量,分光光度法测定一氧化氮(NO)浓度。结果大鼠双侧卵巢切除后,膀胱质量减轻,膀胱黏膜层及肌层明显萎缩、变薄;尿畅舒组大鼠膀胱质量增加,黏膜层细胞排列紧密、层次分明,肌层增厚。空白组、尼尔雌醇组及尿畅舒组血清eNOS、NO均明显高于模型组(P<0.05);尿畅舒组与尼尔雌醇组比较,差异有统计学意义(P<0.05);去势大鼠血清AQP1明显下降,给予雌激素及尿畅舒胶囊后上升;而膀胱AQP1含量在去势前后及给予雌激素、尿畅舒胶囊后差异无统计学意义。结论尿畅舒胶囊可逆转雌激素缺乏导致的膀胱黏膜及平滑肌萎缩,提高血清及膀胱eNOS含量,从而治疗绝经后膀胱过度活动症。

Objective To explore the mechanism of Niaochangshu capsule in the treatment of postmenopausal overactive bladder, through observing its influence on bladder weight and the expression of eNOS and AQP1 of ovariectomized female rats. Methods Female SD rats were divided into blank group, model group, Nilestriol group and Niaochangshu group. Rats were removed ovaries except the blank group. The treatment groups were given corresponding drugs, blank group and model group were given normal saline by gavage. After 4 weeks, the bladders’ weight and thickness were detected, the expressions of Enos and AQP1 in serum and bladder tissue were determined by ELISA, and NO by spectrophotometry. Results Ovariectomy resulted in decreased bladder weight, bladder mucosal and muscular atrophy, and opposite changes showed after given Niaochangshu. The expressions of Enos and NO in bladder and serum were decreased significantly after ovariectomy, while increased by given Niaochangshu capsule or nylestriol （P〈0.05）, and there was significant difference between Niaochangshu group and Nilestriol group （P〈0.05）. The expression of AQP1 was decreased in the model group, and increased after given nylestriol or Niaochangshu capsule. While the expression of AQP1 in bladder had no significant difference among the four groups. Conclusion Niaochangshu capsule can reverse bladder mucosal and muscular atrophy caused by estrogen deficiency, and increase the content of Enos in serum and bladder, thus play the role in the treatment of postmenopausal overactive bladder.